Advertisement

New Perspectives in Genetic Therapies

  • Alain FischerEmail author
Conference paper

Abstract

Advances in genomics over the last years have opened new perspectives in medicine. Applications to the diagnosis of inherited diseases and cancer as well have become a reality, while therapeutic applications emerge. This started with the safe production of therapeutic proteins by genetic engineering of cultured cells now followed by gene therapy. Introduction of therapeutic genes into diseased cells offers the potential to cure monogenic inherited diseases and also to better fight cancer. Thus it is in these two areas that the first proofs of efficacy have been obtained. Ex vivo retrovirus-mediated gene transfer into autologous hematopoietic stem cells has been shown to provide sustained correction of three forms of severe primary immunodeficiencies in about 120 patients up to now. This approach is now extended to the treatment of more prevalent conditions such as hemoglobinopathies. ln vivo gene transfer based on adeno associated viral vectors is being used with some success in the treatment of hemophilia B and of inherited retinopathies as well while being now tested with promise for inherited neuromuscular diseases. Injection of autologous, ex vivo modified T lymphocytes, engineered to express a chimeric antigen receptor (CAR) recognizing a membrane tumor-expressed antigen has been shown to control some forms of leukemia, a promising entry into the treatment of cancer by gene therapy. Genome editing based on engineered nucleases (such as the CRISPR/Cas 9 system) offers additional hopes for gene therapy either through gene inactivation or gene modification (correction). This new technology, however, still requires additional testing to assess its efficacy, notably in nondividing cells as well as its safety because of the potential risk for « off targets ». Some have advocated that this latter technology could be used in the future to fix deleterious mutations in early embryos or even improve health characteristics by gene modification! This approach appears, however, as medically useless in most cases while ethically highly questionable since it implies modification of the germ line genome.

Keywords

Genomics Diagnosis of inherited diseases and cancer Therapeutic applications Genetic engineering Immunodeficiencies In-vivo and ex-vivo retrovirus-mediated gene transfers Ethics 

References

  1. Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341, 1233151.CrossRefGoogle Scholar
  2. Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. New England Journal of Medicine, 360, 447–458.CrossRefGoogle Scholar
  3. Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., Distefano-Pappas, J., et al. (2016). Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: A follow-on phase 1 trial. Lancet, 388, 661–672.CrossRefGoogle Scholar
  4. Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science, 341, 1233158.CrossRefGoogle Scholar
  5. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 326, 818–823.CrossRefGoogle Scholar
  6. Cavazzana-Calvo, M., *, Hacein-Bey, S., *, De Saint Basile, G., Gross, F., Y., E., Nusbaum, P., Selz, F., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. * Equal contribution. Science, 288, 669–672.Google Scholar
  7. Doudna, J. A., & Charpentier, E. (2014). Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 346, 1258096.CrossRefGoogle Scholar
  8. Friedmann, T., & Roblin, R. (1972). Gene therapy for human genetic disease? Science, 175, 949–955.Google Scholar
  9. Hacein-Bey-Abina, S., Hauer, J., Lim, A., Picard, C., Wang, G. P., Berry, C. C., et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. New England Journal of Medicine, 363, 355–364.CrossRefGoogle Scholar
  10. Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., le Deist, F., Wulffraat, N., McIntyre, E., et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New England Journal of Medicine, 348, 255–256.CrossRefGoogle Scholar
  11. Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016). The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature Reviews Clinical Oncology, 13, 273–290.CrossRefGoogle Scholar
  12. Mann, R., Mulligan, R. C., & Baltimore, D. (1983). Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell, 33, 153–159.CrossRefGoogle Scholar
  13. Naldini, L. (2015). Gene therapy returns to centre stage. Nature, 526, 351–360.CrossRefGoogle Scholar
  14. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector [see comments]. Science, 272, 263–267.CrossRefGoogle Scholar
  15. Nathwani, A. C., Reiss, U. M., Tuddenham, E. G., Rosales, C., Chowdary, P., McIntosh, J., et al. (2014). Long-term safety and efficacy of factor IX gene therapy in hemophilia B. New England Journal of Medicine, 371, 1994–2004.CrossRefGoogle Scholar
  16. Orkin, S. H., & Motulsky, A. G. 1995. Report and recommendations of the panel to assess the NIH investment in research on gene therapy. http://www.nih.gov/news/panelrep.html.
  17. Ribeil, J. A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., et al. (2017). Gene therapy in a patient with sickle cell disease. New England Journal of Medicine, 376, 848–855.CrossRefGoogle Scholar
  18. US National Academies. (2017). Consensus report on human genome editing.Google Scholar
  19. Xiao, X., Li, J., & Samulski, R. J. (1996). Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. Journal of Virology, 70, 8098–8108.Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Paris Descartes – Sorbonne Paris Cité University, Imagine InstituteParisFrance
  2. 2.Immunology and Pediatric Hematology Department, Assistance Publique-Hôpitaux de ParisParisFrance
  3. 3.INSERM UMR 1163ParisFrance
  4. 4.Collège de FranceParisFrance

Personalised recommendations